MedPath

Penciclovir

Generic Name
Penciclovir
Brand Names
Denavir
Drug Type
Small Molecule
Chemical Formula
C10H15N5O3
CAS Number
39809-25-1
Unique Ingredient Identifier
359HUE8FJC
Background

Penciclovir is a synthetic acyclic guanine derivative with antiviral activity used for the treatment of various herpes simplex virus (HSV) infections. Displaying low toxicity and good selectivity, penciclovir is a nucleoside analogue.

Indication

Used to treat recurrent cold sores on the lips and face from various herpesvirus invections.

Associated Conditions
Cold Sore
Clinical Trials
Related News

Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant

Phase 1
Not yet recruiting
Conditions
Vaccine Reaction
Interventions
Biological: PCV-LITE
Biological: PCV-LITE+LVA
Biological: PCV20+LVA
First Posted Date
2025-05-22
Last Posted Date
2025-05-22
Lead Sponsor
LiteVax BV
Target Recruit Count
80
Registration Number
NCT06986239

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Phase 3
Not yet recruiting
Conditions
Chickenpox
Interventions
Biological: Candidate varicella vaccine
Biological: Marketed varicella vaccine
First Posted Date
2025-03-03
Last Posted Date
2025-04-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
900
Registration Number
NCT06855160

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Phase 3
Not yet recruiting
Conditions
Chickenpox
Interventions
Biological: Marketed varicella vaccine
Biological: Investigational varicella vaccine
First Posted Date
2025-02-03
Last Posted Date
2025-02-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
600
Registration Number
NCT06806137

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Phase 3
Recruiting
Conditions
Chickenpox
Interventions
Biological: Investigational varicella vaccine_Lot 1
Biological: Investigational varicella vaccine_Lot 2
Biological: Investigational varicella vaccine_Lot 3
Biological: Marketed varicella vaccine_Lot 1
Biological: Marketed varicella vaccine_Lot 2
First Posted Date
2024-12-18
Last Posted Date
2025-03-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1840
Registration Number
NCT06740630
Locations
🇺🇸

GSK Investigational Site, Layton, Utah, United States

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Phase 3
Recruiting
Conditions
Chickenpox
Interventions
Biological: Investigational varicella vaccine
Biological: Marketed varicella vaccine
Biological: Measles, mumps, and rubella vaccine
First Posted Date
2024-11-18
Last Posted Date
2025-01-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
750
Registration Number
NCT06693895
Locations
🇺🇸

GSK Investigational Site, West Covina, California, United States

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Phase 4
Recruiting
Conditions
Lymphoma
Interventions
First Posted Date
2023-09-21
Last Posted Date
2025-05-14
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06049134
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Phase 3
Completed
Conditions
Respiratory Syncytial Virus Infections
Interventions
First Posted Date
2023-05-30
Last Posted Date
2025-05-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1113
Registration Number
NCT05879107
Locations
🇪🇸

GSK Investigational Site, Valencia, Spain

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Phase 3
Completed
Conditions
Pneumococcal Infection
Interventions
First Posted Date
2022-06-21
Last Posted Date
2024-10-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
2663
Registration Number
NCT05425732
Locations
🇺🇸

Baptist Health Center For Clinical Research ( Site 0019), Little Rock, Arkansas, United States

🇺🇸

Millennium Clinical Trials ( Site 0013), Simi Valley, California, United States

🇺🇸

Alliance for Multispecialty Research, LLC ( Site 0015), Coral Gables, Florida, United States

and more 109 locations

A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).

Phase 3
Recruiting
Conditions
Oligodendroglioma
Interventions
Drug: CETEG
Radiation: RT
First Posted Date
2022-04-15
Last Posted Date
2025-01-22
Lead Sponsor
University Hospital Heidelberg
Target Recruit Count
406
Registration Number
NCT05331521
Locations
🇩🇪

University Hospital Cologne, Neurosurgery, Cologne, Germany

🇩🇪

University Hospital Leipzig, Radiation Therapy, Leipzig, Germany

🇩🇪

Helios Hospital Schwerin, Neurosurgery, Schwerin, Germany

and more 16 locations

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

Phase 3
Recruiting
Conditions
Oligodendroglioma
Low-grade Oligodendroglioma
1p19q Codeletion
Interventions
Drug: Radiotherapy and PCV chemotherapy
First Posted Date
2021-01-11
Last Posted Date
2025-03-13
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
280
Registration Number
NCT04702581
Locations
🇫🇷

CHU d'Amiens-Picardie Site Sud, Amiens, France

🇫🇷

Institut de Cancerologie de l'Ouest, Saint-Herblain, France

🇫🇷

CHU de Bordeaux Hôpital Saint André, Bordeaux, France

and more 22 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy